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in this trial was not sufﬁcient to overcome
the unfavourable impact of non-sudden
deaths in the ICD arm, resulting in an
overall neutral outcome. The experience of
the DINAMIT trial4 clearly pointed out the
importance, especially in a heart failure
population, of considering total mortality
as primary outcome, avoiding the pitfalls of
considering only sudden death reduction.
On the basis of the abovementioned
considerations, it becomes clear that the
third recommendation should be corrected
by deleting the phrase ‘sudden death’ and
replacing it by ‘total mortality’.
We feel strongly about correcting
this error, not only because it is a
misinterpretation of the pertinent trial
outcomes, but more importantly, because
it implicitly underestimates the importance
of ICD therapy in the heart failure
population, as demonstrated by these land-
mark studies.
Thank you for your consideration.
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The Task Force for the Diagnosis and
Treatment of Chronic Heart Failure of
the European Society of Cardiology:
Guidelines for the Diagnosis and
Treatment of Chronic Heart Failure:
reply
Dr Krum suggests changes to the ESC
Guidelines on the diagnosis and treatment
of chronic heart failure and of Figure 4 in
particular. We appreciate the opportunity
to clarify the role of the ﬁgure. As stated
in the legend, the ﬁgure should be viewed
as an example for decision-making. The
ﬁgure is designed to complement the expla-
natory text, but is no substitute for it. In the
text and in Table 18, it is stated (as pointed
out by Krum) that the addition of an angio-
tensin receptor blocker (ARB) should be con-
sidered in symptomatic patients regardless
of background angiotensin-converting
enzyme (ACE)-inhibitor therapy. The reason
for not stating that ACE-inhibitor/ARB
should be used in combination in the ﬁgure
is that these patients require re-evaluation
after the institution of basic therapy and
only those with persisting NYHA class-II
symptoms should, in the absence of an indi-
cation for an ARA, then receive an ARB.
Similarly, Figure 4 uses the term ‘post MI’
and this is clariﬁed as meaning ‘recent MI’ in
both tables and text.
Dr Gasparini and co-workers propose that
the recommendations for the beneﬁts of
ICDs should be extended to include ‘all-
cause’ mortality and not only applied to
sudden death. In the full text document
(www.escardio.org/knowledge/guidelines),
the background documentation on all-cause
mortality is expanded. The statistical evi-
dence for a reduction in sudden death and
all-cause mortality in patients with heart
failure and reduced left ventricular function
cannot refute the size of the beneﬁt, the
fact that most patients who receive such a
device will not beneﬁt and because all
patients will be exposed to the considerable
morbidity associated with deﬁbrillators.
Much of these data are new, including the
DINAMIT study which was included through
a meta-analysis, and have yet to be placed
in the context of other treatments that can
reduce mortality in patients with heart
failure, including pharmacological therapy
and cardiac resynchronization devices.
These constitute important gaps in know-
ledge about an intervention, which has a
modest effect on mortality and considerable
morbidity. Accordingly, the Task Force
felt strongly that the selection of patients
in whom the beneﬁts of a deﬁbrillator
outweighed the adverse effects required
considerable expertise and ﬁne judgement on
the part of the clinician and that no general
mandate could be given at present.
Every clinician and medical system has to
interpret this new and innovative technology
in the light of their competence, resources,
and priorities. The difﬁculties have been
recognized in a recent review.1 Guidelines
can guide on such matters, but not decide
for individual patient care.
More information exists on the diagnosis
and treatment of heart failure than most
other areas of medicine. This abundance of
evidence is complex to interpret,may be con-
ﬂicting at times, but does provide a basis for
making some strong recommendations.
However, the information is still imperfect,
reﬂecting the need for further research.2
Clinical judgement is always important for
the ﬁnal decision. Guidelines provide a
framework for clinical practice and training,
but are no substitute for personal expertise.
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Evidence-based vs. ‘impressionist’
medicine: how best to implement
guidelines
Bassand et al.1 make a good case for
increased use of guidelines. However, they
underestimate the role for clinical judge-
ment, patient choice, and physician concerns
about cost effectiveness and polypharmacy.
Randomized clinical trials andmeta- analyses
have enormously improved the data base
to allow guidelines to be formulated and
improve knowledge in pathophysiology and
therapeutics in so many countless areas. For
this, all clinicians are grateful. However, on
a daily basis, the clinician has to make
decisions for the individual patient and does
not always have the same conﬁdence as the
guideline makers that the patient ﬁts the
criteria for a speciﬁc pathway. Even more
importantly, because the morbidity/mortality
beneﬁt is likely to be so small, the odds are
very strong and the individual patient is
most unlikely to beneﬁt. When one presents
the numbers needed to treat (NNT) for a
beneﬁt to the patient, they are frequently
unimpressed and opt not to proceed.
Clinicians will regularly opt to compromise,
sensibly in our view, with the patient and
choose a more user friendly regime to
facilitate compliance.
All will agree that the health authorities
and the professionals should collaborate to
facilitate guideline development and ration-
alization to guard against guideline over-
load. We have reservations about industry
being involved in guideline development
and promotion, as historically their pro-
motions have emphasized relative risk
reduction with little reference to absolute
reduction and NNT. We would suggest that
information on numbers treated effectively
and ineffectively should also stand side by
side. For a counter opinion, we would
recommend the work of James Penston.2
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Evidence-based vs. ‘impressionist’
medicine: how best to implement
guidelines: reply
Drs Fennell and Worrall make interesting and
valuable comments on our recent paper,1
which was intended only as an editorial,
stressing the wide discrepancy between the
recommendations to treat and the actual
implementation of guidelines. This lack of
implementation can result in loss of beneﬁt
for patients who are under treated. The
impact of under use of medical therapies
or strategies with proven efﬁcacy on immedi-
ate and long-term outcome has been amply
documented. We based our assumptions on
some of the critical areas of our discipline,
particularly acute coronary syndromes,
where the life of the patient is at stake, and
also heart failure. Registries have proven
that in the ﬁeld of acute coronary syndromes,
poor compliance with guidelines can result in
a two-fold increase in mortality at 1 month
and 1 year. It is, therefore, the duty of
every physician to implement guidelines,
when one is absolutely certain that they will
have a positive impact on the life expectancy
of the patient.
This said, we understand the concerns of
Drs Fennell and Worrall about the involve-
ment of the industry in the development of
implementation programmes. From a purely
pragmatic point of view, it can be acknowl-
edged that little or no funds are provided
by health authorities to promote best prac-
tice through implementation programmes
for guidelines, although some initiatives sup-
ported by health authorities are beginning in
Europe.
The most important remark by our col-
leagues Fennell and Worrall is about the
strength of evidence of recommended thera-
pies included in guidelines. They propose
that it could be based more on the number
needed to treat (NNT), which may reﬂect the
cost effectiveness of a given treatment. This
comment is certainly valid, and indeed, NNT
and also number needed to harmwill be incor-
porated in a future set of guidelines to be
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